{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:17:28Z","timestamp":1770743848162,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.bulcan.2022.04.003","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:53:24Z","timestamp":1655452404000},"page":"862-872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recommandations 2022\u00a0du groupe Fi-LMC pour la gestion du risque d\u2019\u00e9v\u00e9nements cardiovasculaires sous ponatinib dans la leuc\u00e9mie my\u00e9lo\u00efde chronique"],"prefix":"10.1016","volume":"109","author":[{"given":"Delphine","family":"R\u00e9a","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Messas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"Mirault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck Emmanuel","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.bulcan.2022.04.003_bib0155","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"issue":"8962","key":"10.1016\/j.bulcan.2022.04.003_bib0160","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(95)92596-1","volume":"345","author":"Allan","year":"1995","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.bulcan.2022.04.003_bib0165","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.04.003_bib0170","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","volume":"1","author":"Bixby","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"18","key":"10.1016\/j.bulcan.2022.04.003_bib0175","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1182\/blood-2012-04-423418","article-title":"Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"121","author":"Hochhaus","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2022.04.003_bib0180","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.bulcan.2022.04.003_bib0185","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bulcan.2022.04.003_bib0190","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.24360","article-title":"Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.bulcan.2022.04.003_bib0195","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"PACE Investigators. A phase 2\u00a0trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2022.04.003_bib0200","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2\u00a0PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bulcan.2022.04.003_bib0205","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2\u00a0or more prior TKIs","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2022.04.003_bib0210","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European Leukemia Net 2020\u00a0recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bulcan.2022.04.003_bib0215","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","article-title":"Trends in chronic myeloid leukemia incidence and survival in the United States from 1975\u00a0to 2009","volume":"54","author":"Chen","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.bulcan.2022.04.003_bib0220","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicenter Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2022.04.003_bib0225","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2022.04.003_bib0230","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00277-015-2318-y","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"94","author":"Rea","year":"2015","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.bulcan.2022.04.003_bib0235","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.bulcan.2022.04.003_bib0240","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2\u00a0clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.bulcan.2022.04.003_bib0245","doi-asserted-by":"crossref","first-page":"7550","DOI":"10.1200\/JCO.2020.38.15_suppl.7550","article-title":"An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia","volume":"38","author":"Januzzi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.bulcan.2022.04.003_bib0250","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2022.04.003_bib0255","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"issue":"14","key":"10.1016\/j.bulcan.2022.04.003_bib0260","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jacc.2009.07.020","article-title":"Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians","volume":"54","author":"Cooney","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"34","key":"10.1016\/j.bulcan.2022.04.003_bib0265","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J."},{"issue":"9","key":"10.1016\/j.bulcan.2022.04.003_bib0270","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1016\/S2352-3026(15)00127-1","article-title":"Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2\u00a0study","volume":"2","author":"Jain","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bulcan.2022.04.003_bib0275","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fcvm.2018.00055","article-title":"The BCR-ABL1\u00a0Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model","volume":"5","author":"Pouwer","year":"2018","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.bulcan.2022.04.003_bib0280","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.thromres.2014.11.009","article-title":"The BCRABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear","volume":"135","author":"Loren","year":"2015","journal-title":"Thromb Res"},{"issue":"7","key":"10.1016\/j.bulcan.2022.04.003_bib0285","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the 2nd generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia","volume":"99","author":"Rea","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bulcan.2022.04.003_bib0290","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000504664","article-title":"Management of ponatinib in patients with chronic myeloid leukemia with cardiovascular risk factors","volume":"64","author":"Santoro","year":"2019","journal-title":"Chemotherapy"},{"issue":"3","key":"10.1016\/j.bulcan.2022.04.003_bib0295","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2022.04.003_bib0150","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jacc.2009.09.081","article-title":"Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we?","volume":"56","author":"Shah","year":"2010","journal-title":"J Am Coll Cardiol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122001539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122001539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:36:25Z","timestamp":1757792185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122001539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":30,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0007455122001539"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.04.003","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommandations 2022\u00a0du groupe Fi-LMC pour la gestion du risque d\u2019\u00e9v\u00e9nements cardiovasculaires sous ponatinib dans la leuc\u00e9mie my\u00e9lo\u00efde chronique","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}